Cargando…

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap

OBJECTIVE: To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. MATERIALS AND METHODS: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The result...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franca, Carlos Antônio da Silva, Vieira, Sérgio Lannes, Carvalho, Antonio Carlos Pires, Bernabe, Antonio Jose Serrano, Penna, Antonio Belmiro Rodrigues Campbell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337165/ https://www.ncbi.nlm.nih.gov/pubmed/25741055 http://dx.doi.org/10.1590/S0100-39842014000200010

Ejemplares similares

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’
por: Ahmed, Kamran A, et al.
Publicado: (2014)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure
por: Shah, T T, et al.
Publicado: (2016)

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Reduction of Serum Concentrations and Synergy between Retinol, β-Carotene, and Zinc According to Cancer Staging and Different Treatment Modalities Prior to Radiation Therapy in Women with Breast Cancer
por: Rosa, Cintia, et al.
Publicado: (2019)

Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2022)

The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery
por: Zeng, Jing, et al.
Publicado: (2017)

Predictive factors of (18)F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?
por: Johnson, Alison C., et al.
Publicado: (2016)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
por: Wu, Kai-Jie, et al.
Publicado: (2018)

Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer
por: Kang, Sokbom, et al.
Publicado: (2011)

The leucocyte nadir, a predictor of chemotherapy efficacy?
por: Kvinnsland, S
Publicado: (1999)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

Intra-operative ocular ultrasonography of iodine-125 brachytherapy plaques in patients with uveal melanoma
por: Ces, Antonio Piñeiro, et al.
Publicado: (2021)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer
por: Nakamura, Kazuto, et al.
Publicado: (2020)

Iodine-125 brachytherapy for brain tumours - a review
por: Schwarz, Silke B, et al.
Publicado: (2012)

Iodine-125 seed implantation in the treatment of malignant tumors
por: Hu, Pan, et al.
Publicado: (2023)

Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model
por: Brun, Thomas, et al.
Publicado: (2018)

A Case of Iodine 125 Seeds (I-125) Responding to Lung Squamous Cell Carcinoma
por: Ni, Qingtao, et al.
Publicado: (2022)

Nadir hemoglobin is associated with poor outcome from intracerebral hemorrhage
por: Chang, Tiffany R, et al.
Publicado: (2013)

Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
por: Gregório, Emerson Pereira, et al.
Publicado: (2019)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Medical knowledge on ionizing radiations
por: Carvalho, Antonio Carlos Pires
Publicado: (2014)

Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
por: Chrastina, Adrian, et al.
Publicado: (2010)

A Robust Oxygen Microbubble Radiosensitizer for Iodine‐125 Brachytherapy
por: Peng, Sheng, et al.
Publicado: (2021)

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions
por: Wei, Shuhua, et al.
Publicado: (2021)

Histopathology of Intraocular Medulloepithelioma following Iodine-125 Plaque Brachytherapy
por: Mohan, Sukriti, et al.
Publicado: (2022)

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma
por: Wang, Congxiao, et al.
Publicado: (2022)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Iodine Supplementation in the Newborn
por: Ghirri, Paolo, et al.
Publicado: (2014)

Association of Admission, Nadir, and Terminal Donor Creatinine With Kidney Transplantation Outcomes
por: Irish, Georgina L., et al.
Publicado: (2021)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Comparison of Iodine-125 Seed Implantation and Pancreaticoduodenectomy in the Treatment of Pancreatic Cancer
por: Liu, Kai, et al.
Publicado: (2014)

Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy
por: Fang, Rui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ca9iqetjf95k51q8u96qurhi0u